Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase NA 1

Status

Recruiting 6Completed 6Active not recruiting 5Not yet recruiting 1Available 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 3Other solid neoplasm 2Tumor-Agnostic 1

Conditions

Solid Tumors 2Stomach Neoplasms 1Neoplasms 1CLDN18.2-positive Gastric Adenocarcinoma 1CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction 1Adenocarcinoma 1

Interventions

Cyclophosphamide 1499Cisplatin 1435Paclitaxel 1340Radiotherapy 1310Carboplatin 1267Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 700Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Completed × zolbetuximab × Clear all
NCT01630083 2025-06-15

FAST

Astellas Pharma Inc

Phase 2 Completed
252 enrolled
Gastrointestinal

CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction

NCT01197885 2025-06-13

Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal Cancer

Astellas Pharma Inc

Phase 2 Completed
54 enrolled
Other solid neoplasm

Solid Tumors

NCT03528629 2024-12-02

A Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma

Astellas Pharma Inc

Phase NA Completed
18 enrolled
Gastrointestinal

Neoplasms, Stomach Neoplasms

NCT00909025 2024-11-21

Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal Cancer

Astellas Pharma Inc

Phase 1 Completed
15 enrolled
Other solid neoplasm

Solid Tumors

NCT04086758 2024-11-20

A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma

Astellas Pharma Inc

Phase 1 Completed
12 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT01671774 2024-11-14

PILOT

Astellas Pharma Inc

Phase 1 Completed
29 enrolled
Gastrointestinal

CLDN18.2-positive Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡